Keywords: ThromboGeneics, Ocriplasmin, VMA, USA, FDA, Eisai, Zonegran, Epilepsy, Monotheapy, Pediatric, EMA

News briefs: Priority review for ocriplasmin; Zonegran monotherapy in EU

Article | 03 July 2012

Print This

Belgium-based biopharma firm ThromboGenics (Euronext Brussels: THR) says that the US Food and Drug Administration has officially accepted the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in